Relmada halts depression drug trials, shifts focus to psilocybin program amid review
The drug developer will maintain its psilocybin program while probing options for the future, including potentially selling.
The post Relmada halts depression drug trials, shifts focus to psilocybin program amid review appeared first on Green Market Report.
